Summary
The development of a sensitive radioimmunoassay for the determination of lisuride in plasma is described. The antiserum against lisuride-4-hemisuccinate-BSA was raised in rabbits. Using this method the plasma levels of lisuride were monitored following one intravenous (25 µg) and two oral (100 µg and 300 µg) doses of lisuride hydrogen maleate in three female and three male volunteers (intraindividual comparison). The plasma prolactin was also determined by radioimmunoassay. Following i. v. injection, the concentration of lisuride declined in three phases, with half-lives of 5 min, 25 min and 2 h. The total plasma clearance of 800±250 ml × min−1 was in the range of “plasma flow” through the liver. In agreement with the high rate of biotransformation, the bioavailability of lisuride administered orally was 10%±7% of the 100-µg dose, and 22%±7% of the 300-µg dose. The plasma prolactin was lowered to 3%–18% of its pretreatment value depending on the route of administration and the dose. The reduction appeared to be short-lived and to be directly dependent on the plasma concentration of lisuride. Following intravenous injection, the prolactin level declined after a so far unexplained lagtime of 0.5 h.
Similar content being viewed by others
References
Kehr W, Speckenbach W (1978) Effect of lisuride and LSD on monoamine synthesis after axotomy or reserpine treatment in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 301: 163–169
Keller HH, Da Prada M (1979) Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine. Life Sci. 24: 1211–1222
Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 36: 373
Horowski R, Wendt H, Gräf K-J (1978) Prolactin-lowering effect of low doses of lisuride in man. Acta Endocrinol 87: 234–240
Hardt W, Schmidt-Gollwitzer M, Horowski R (1979) Suppression of Lactation with Lisuride. Gynecol Invest 10: 95–105
Bohnet HG, Hanker JP, Horowski R, Wickings EJ, Schneider HPG (1979) Suppression of Prolactin Secretion by Lisuride throughout the Menstrual Cycle and in Hyperprolactinemic Menstrual Disorders. Acta Endocrinol 92: 8–19
Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gräf KJ, Horowski R (1978) Lisuride Hydrogen Maleate: Evidence for a Long Lasting Dopaminergic Activity in Humans. J Clin Endocrinol Metab 46: 196–202
Liuzzi A, Chiodini P, Verde GG, Cozzi R, Botalla L, Rainer E (1980) Effectiveness of the Dopamine Agonist Lisuride in the Treatment of Acromegaly and Pathological Hyperprolactinemic States. Endocrinol Invest 4: 405–414
Sinha YN, Shelby FW, Lewis UJ, Van Der Laan WP (1973) Homologous radioimmunoassay for Human Prolactin. J Clin Endocrinol 36: 506
Habeeb AFSA (1966) Determination of Free Amino-groups in Proteins by Trinitrobenzenesulfonic Acid. Anal Biochem 14: 328–336
Toda T, Oshino N (1981) Biotransformation of Lisuride in the Hemoglobin-Free Perfused Rat Liver and in the Whole Animal. Drug Metab Dispos (in press)
Hümpel M, Toda T, Oshino N, Pommerenke G (1981) The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey. Eur J Drug Metab Pharmacokinet (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hümpel, M., Nieuweboer, B., Hasan, S.H. et al. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level. Eur J Clin Pharmacol 20, 47–51 (1981). https://doi.org/10.1007/BF00554666
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00554666